Varying effectiveness.

Moderna has announced a new bivalent booster that now targets Beta-specific variants, demonstrating double the antibody response at 1 and 6 months against current COVID-19 variants when compared to the original vaccine booster, with further data anticipated soon on a Omicron-specific bivalent vaccine. | Chalkias, Research Square 2022


Popular Posts